SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
A phase 2 trial of SCIB1 or iSCIB1+ DNA vaccine in melanoma, run by Scancell Ltd, active and no longer recruiting.
Overview
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) is a phase 2 interventional study registered as NCT04079166 by Scancell Ltd, with 173 participants enrolled, started 2019-08-19 and due to reach its primary completion in 2027-01-31. Interventions recorded: SCIB1 or iSCIB1+ DNA vaccine.
Similar pages
not linked directly; found by shared links- TrialModi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
Shares Scancell and the tag pipeline.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares Melanoma and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialNeoadjuvant L19IL2/L19TNF- Pivotal Study
Shares Melanoma and the tag pipeline.
- TrialEfficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Shares Melanoma and the tag pipeline.
- TrialAMT-253 in Patients With Advanced Solid Tumours
Shares Melanoma and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Shares Melanoma and the tag pipeline.
- TrialSafety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.